title: Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
abstract: BACKGROUND
  Breast cancer is very common and highly fatal in women. Current non-invasive detection methods like mammograms are unsatisfactory. Lipidomics, a promising detection method, may serve as a novel prognostic approach for breast cancer in high-risk patients.
  
  
  RESULTS
  According the predictive model, the combination of 15 lipid species had high diagnostic value. In the training set, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the combination of these 15 lipid species were 83.3%, 92.7%, 89.7%, and 87.9%, respectively. The AUC in the training set was 0.926 (95% CI 0.869-0.982). Similar results were found in the validation set, with the sensitivity, specificity, PPV and NPV at 81.0%, 94.5%, 91.9%, and 86.7%, respectively. The AUC was 0.938 (95% CI 0.889-0.986) in the validation set.
  
  
  METHODS
  Using triple quadrupole liquid chromatography electrospray ionization tandem mass spectrometry, this study was to detect global lipid profiling of a total of 194 plasma samples from 84 patients with early-stage breast cancer (stage 0-II) and 110 patients with benign breast disease included in a training set and a validation set. A binary logistic regression was used to build a predictive model for evaluating the lipid species as potential biomarkers in the diagnosis of breast cancer.
  
  
  CONCLUSIONS
  The combination of these 15 lipid species as a panel could be used as plasma biomarkers for the diagnosis of breast cancer.
authors.affiliation: Department of Clinical Laboratory, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou City, Guangxi Province, China.|Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
authors.forename: Hankui
authors.initials: H
authors.lastname: Chen
authors.affiliation: Department of Clinical Laboratory, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou City, Guangxi Province, China.|Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
authors.forename: Meiyu
authors.initials: M
authors.lastname: Dai
authors.affiliation: Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
authors.forename: Junmei
authors.initials: J
authors.lastname: Ai
authors.affiliation: Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Pathology, Rush University Medical Center, Chicago, Illinois, USA.
authors.forename: Brett
authors.initials: B
authors.lastname: Mahon
authors.affiliation: Department of Clinical Laboratory, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou City, Guangxi Province, China.
authors.forename: Shengming
authors.initials: S
authors.lastname: Dai
authors.affiliation: Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.|Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA.|Medical College, Wuhan University of Science and Technology, Wuhan, Hubei Province, China.
authors.forename: Youping
authors.initials: Y
authors.lastname: Deng
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001941:Breast Diseases / Q000097:blood* / Q000175:diagnosis; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis; D002853:Chromatography, Liquid / Q000379:methods; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods
chemical_list: D014408:Biomarkers, Tumor; D008055:Lipids
keywords: benign lesion; biomarker; breast cancer; lipidomics; plasma